자발적 의약품 부작용 보고자료를 이용한 성별에 따른 부작용 발현 차이 = Sex Differences in Adverse Drug Reactions Using the Korea Institute of Drug Safety and Risk Management Database

다국어 초록 (Multilingual Abstract)

The aim of this study was to assess and characterize sex differences in adverse drug reactions (ADRs) reported to the Korea Institute of Drug Safety and Risk Management (KIDS). This retrospective pharmacoepidemiological study was performed using the Korea Adverse Event Reporting System (KAERS) database from the KIDS in 2014-2018. Variables used in the analyses include sex and age of patients, suspected drug, type and severity of ADR, and severity of ADR. A ratio of reports concerning women and men was calculated for ADRs reported. A dataset of 22 drugs selected from the FDA label and UpToDate？？ database were requested to KIDS. Among 22 drugs, 17 of them were reported as suspected drugs to cause ADR and these were further analyzed in detail. The total reported number of ADRs was 241,974 and reports from female patients comprised of 54.5%. Aprepitant had the highest number of ADR reports (n=179,716), followed by fluorouracil (n=17,807), oxycodone (n=14,643) and cisplatin (n=14,191). Reports of serious adverse events were mostly from aprepitant and evidently high in female patients in aprepitant. Sex differences exist in ADRs based on KIDS-KAERS database which varies among drugs and type of ADRs. Further studies are warranted to examine details of clinical information of patients to conclude gender differences in adverse drug reactions.

목차 (Table of Contents)

• 서 론(Introduction) 연구 방법(Research Methods) 결 과(Results) 고 찰(Discussion) 결 론(Conclusion) 감사의 말씀(Acknowledgment) Conflict of Interest 참고문헌

참고문헌 (Reference)

1 이수진, "의약품 사용 관련 국내 통계자료에 나타난 성별 차이 조사 연구" 한국임상약학회 23 (23): 114-122, 2013

2 De Jongh, F. E., "Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients" 88 : 1199-, 2003

3 Kamil, N., "Toxic effects of multiple anticancer drugs on skin" 23 : 7-, 2010

4 Yu, Y., "Systematic Analysis of Adverse Event Reports for Sex Differences in Adverse Drug Events" 6 : 24955-, 2016

5 Giagnuolo, G., "Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting(CINV)in pediatric Hodgkin Lymphoma" 14 : e0215295-, 2019

6 Grath, S., "Sex-Biased Gene Expression" 50 : 29-, 2016

7 Soldin, O. P., "Sex differences in pharmacokinetics and pharmacodynamics" 48 : 143-, 2009

8 Gilks, W. P., "Sex differences in disease genetics : evidence, evolution, and detection" 30 : 453-, 2014

9 de Vries, S. T., "Sex differences in adverse drug reactions reported to the National Pharmacovigilance Centre in the Netherlands: An explorative observational study" 85 : 1507-, 2019

10 Ekhart, C., "Sex Differences in Reported Adverse Drug Reactions of Selective Serotonin Reuptake Inhibitors" 41 : 677-, 2018

11 Hilliard, L. M., "Retinal toxicity associated with cisplatin and etoposide in pediatric patients" 28 : 310-, 1997

12 Kaiko, R. F., "Pharmacokineticpharmacodynamic relationships of controlled-release oxycodone" 59 : 52-, 1996

13 Yu, Y. M., "Patterns of Adverse Drug Reactions in Different Age Groups : Analysis of Spontaneous Reports by Community Pharmacists" 10 : e0132916-, 2015

14 Eiseman, A. S., "Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil" 19 : 216-, 2003

15 Miller, D. F., "Ocular and orbital toxicity following intracarotid injection of BCNU (carmustine) and cisplatinum for malignant gliomas" 92 : 402-, 1985

16 Berger, M. J., "NCCN Guidelines Insights: Antiemesis, Version 2.2017" 15 : 883-, 2017

17 Molassiotis, A., "MASCC/ESMO Antiemetic Guidelines : Introduction to the 2016guideline update" 25 : 267-, 2017

18 Prasad, S., "Lacrimal canalicular stenosis associated with systemic 5-fluorouacil therapy" 78 : 110-, 2000

19 Andreassen, T. N., "Influences on the pharmacokinetics of oxycodone : a multicentre cross-sectional study in 439 adult cancer patients" 67 : 493-, 2011

20 Zalcberg, J., "Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group" 34 : 1871-, 1998

21 Kando, J. C., "Gender as a risk factor for adverse events to medications" 50 : 1-, 1995

22 Mojaverian, P., "Effect of food on the absorption of enteric-coated aspirin: correlation with gastric residence time" 41 : 11-, 1987

23 Chansky, K., "Differences in toxicity between men and women treated with 5-fluorouracil therapy for colorectal carcinoma" 103 : 1165-, 2005

24 Mey, U. J. M., "Dexamethasone, High-Dose Cytarabine, and Cisplatin in Combination with Rituximab as Salvage Treatment for Patients with Relapsed or Refractory Aggressive Non-Hodgkin's Lymphoma" 24 : 593-, 2006

25 Payne, A. S., "Dermatologic toxicity of chemotherapeutic agents" 33 : 86-, 2006

26 Sanborn, R. E., "Cutaneous reactions to chemotherapy: commonly seen, less described, little understood" 26 : 103-, 2008

27 "Chemocare"

28 Dando, T. M., "Aprepitant: a review of its use in the prevention of chemotherapy-induced nausea and vomiting" 64 : 777-, 2004

29 FDA Drug Label, "Aprepitant(EMEND)"

30 Basch, E., "Antiemetics : American Society of Clinical Oncology clinical practice guideline update" 29 : 4189-, 2011